Peripheral TIGIT+ T Follicular Helper Cells That Produce High Levels of Interleukin-21 via OX40 Represent Disease Activity in IgG4-Related Disease

Mitsuhiro Akiyama¹, Katsuya Suzuki¹, Keiko Yoshimoto¹, Hidekata Yasuoka², Yuko Kaneko¹ and Tsutomu Takeuchi¹∗

¹ Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ² Division of Rheumatology, Department of Internal Medicine, Fujita Health University School of Medicine, Aichi, Japan

**Objectives:** Multiple studies suggest that interleukin (IL)-21 plays a pivotal role in the differentiation of B cells and activation of cytotoxic T cells and is involved in the pathogenesis of IgG4-related disease (IgG4-RD). T cell immunoreceptor with immunoglobulin and ITIM domain (TIGIT) is a new marker of T follicular helper (Tfh) cells, yet its significance remains unknown. The objective of this study was to investigate whether TIGIT expression could detect high IL-21-producing peripheral Tfh populations and their association with disease activity in IgG4-RD.

**Methods:** TIGIT expression in peripheral CD4+T cell subsets was comprehensively analyzed by multi-color flow cytometry. Single cell mapping was performed by t-SNE method, and IL-21 production was compared in TIGIT+ and TIGIT-T cells. The effect of OX40 signal on cytokine expression was analyzed by RNA-sequencing. Clinical significance of TIGIT+ and TIGIT- peripheral T cells was analyzed in active patients with IgG4-RD, both at baseline and after 12 weeks of glucocorticoid treatment.

**Results:** Unbiased single cell mapping revealed two high IL-21-producing peripheral T cell populations; TIGIT+ Tfh and TIGIT-T helper cells. OX40 signal was associated with high IL-21 production in TIGIT+ Tfh and TIGIT-T helper cells. IL-21 production in Tfh cells correlated with the proportion of TIGIT+ cells in Tfh cells, serum IgG4 level, and scores of disease activity. Furthermore, the skewing toward peripheral TIGIT+ Tfh cells, particularly TIGIT+Tfh2 subset correlated with disease activity and was corrected by glucocorticoid treatment in IgG4-RD.

**Conclusions:** OX40 is associated with high IL-21 production in peripheral TIGIT+ Tfh cells, and the increase in peripheral TIGIT+ Tfh cells reflects disease activity in IgG4-RD.

Keywords: TIGIT, T follicular helper cells, interleukin-21, OX40, IgG4-related disease, disease activity, TPH
INTRODUCTION

IgG4-related disease (IgG4-RD) is a fibro-inflammatory disease characterized by storiform fibrosis, IgG4+ plasma cell infiltration, and elevated levels of serum IgG4 (1–4). Mounting evidence has revealed that T follicular helper (Tfh) cells, which induce hyperplastic tertiary lymphoid organ formation, IgG4 class-switching, and plasma cell differentiation, are involved in the pathogenesis of IgG4-RD (5–15). In addition, CD4+ cytotoxic T cells cause tissue damage and fibrosis (16–19).

The expression of interleukin-21 (IL–21) is upregulated in the affected tissues of IgG4-RD patients (20). IL–21 is produced by CD4+ T cells, with high production by Tfh cells, and plays a key role in B cell differentiation and maturation and in enhancing the activity and survival of CD4+ cytotoxic T cells (21, 22). IL-21-producing Tfh cells thus may be a key immune cell subset involved in the pathogenesis of IgG4-RD.

Tfh cells in the peripheral blood of humans have been found to be CXCR5-positive, enabling their study (23, 24). Tfh cells can be divided into sub-populations according to their surface markers, including interferon-γ-producing Tfh1 (CXCR3+CXC-R6+), IL-4-producing Tfh2 (CXCR3-CCR6-) and IL-17-producing Tfh17 (CXCR3-CCR6+) (23, 24). Given that IL–21 plays a crucial role in the pathogenesis of IgG4-RD, we speculated that surface markers for IL-21-producing peripheral Tfh populations are likely surrogate markers for Tfh responses and may therefore be useful in the assessment of disease activity.

T cell immunoreceptor with immunoglobulin and ITIM domain (TIGIT) is a co-inhibitory receptor that is expressed on T cells and natural killer cells (25). Some studies have suggested that TIGIT expression can be detected on Tfh cells (26, 27). However, the usefulness of TIGIT expression as a surface marker of human peripheral Tfh cells remains unknown.

Here, we investigated the association of TIGIT with IL-21-producing CD4+ T cells in the peripheral blood of patients with IgG4-RD (Supplementary Table 1). Disease activity was assessed based on the IgG4-RD responder index (IgG4-RD RI) score (31). Healthy individuals were confirmed to have no autoimmune diseases, allergic disorders, malignancies, or infections. This study was approved by the ethics committee of Keio University School of Medicine and carried out in accordance with the Declaration of Helsinki. Written informed consent was obtained from all patients and healthy individuals.

Patients and Methods

Twenty-three consecutive patients with untreated, active IgG4-RD (Supplementary Table 1), and 21 healthy individuals were included in this study. All patients with IgG4-RD fulfilled the 2011 comprehensive IgG4-RD diagnostic criteria or the 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-RD (28–30). Disease activity was assessed based on the IgG4-RD responder index (IgG4-RD RI) score (31). Healthy individuals were confirmed to have no autoimmune diseases, allergic disorders, malignancies, or infections. This study was approved by the ethics committee of Keio University School of Medicine and carried out in accordance with the Declaration of Helsinki. Written informed consent was obtained from all patients and healthy individuals.

MATERIALS AND METHODS

Patients and Methods

Twenty-three consecutive patients with untreated, active IgG4-RD (Supplementary Table 1), and 21 healthy individuals were included in this study. All patients with IgG4-RD fulfilled the 2011 comprehensive IgG4-RD diagnostic criteria or the 2019 American College of Rheumatology/European League Against Rheumatism classification criteria for IgG4-RD (28–30). Disease activity was assessed based on the IgG4-RD responder index (IgG4-RD RI) score (31). Healthy individuals were confirmed to have no autoimmune diseases, allergic disorders, malignancies, or infections. This study was approved by the ethics committee of Keio University School of Medicine and carried out in accordance with the Declaration of Helsinki. Written informed consent was obtained from all patients and healthy individuals.

Immunophenotyping of Peripheral CD4+ T Cells

To determine TIGIT expression on each CD4+ T cell subset, frozen PBMCs which were cryopreserved in liquid nitrogen were thawed first and stained the cells with fluorescently labeled antibodies for 15 minutes and then analyzed cell populations by multi-color flow cytometry. Dead cells were excluded by a lower level of forward scatter found at the bottom left corner of the density plot according to the guidelines for the use of flow cytometry and cell sorting in immunological studies (32). For OX40 and PD-1 expression analysis, heparinized whole blood samples were stained for 15 minutes with the antibodies and red blood cells were lysed with FACS Lysing Solution (BD Biosciences). The antibodies used for this study are shown in Supplementary Table 2. The definition of each CD4+ T cell subset is shown in Supplementary Table 3.

For intracellular staining for IL-21 or surface staining for PD-L1, PBMCs were freshly purified using gradient centrifugation with a Ficoll-Paque Plus (GE Healthcare). CD4+ T cells were enriched from PBMCs using a CD4+ T cell isolation kit (Miltenyi Biotec) according to the manufacturer’s instructions, and then cultured in 96-well round-bottom plates in RPMI 1640 medium supplemented with 10% heat-inactivated fetal bovine serum. The cells were maintained in a humidified atmosphere at 37°C with 5% CO2. Cells (2×10⁵/200 µL/well) were stimulated for 4 hours with phorbol myristoyl acetate (PMA) (Sigma, St. Louis) [50 ng/ml] and ionomycin (Sigma, St. Louis) [1 µg/ml] along with Golgistop (BD Biosciences) [4 µl of BD Golgistop™ for every 6 mL of cell culture]. Following stimulation, CD4+ T cells were stained for 30 minutes with antibodies specific for cell-surface markers for Tfh and Th cell subsets and BV510- conjugated anti-human PD-L1 (Clone 29E.2A3; BioLegend) (Supplementary Table 3). Cells were then fixed and permeabilized with Intracellular Fixation & Permeabilization Buffer Set (eBioscience) according to the manufacturer’s protocol, and then incubated with APC-conjugated anti-human IL-21 (Clone 3A3-N2; BioLegend) for 40 minutes. Cells were then washed and analyzed using an LSRFortessa X-20 (BD Biosciences) flow cytometer. Data were analyzed using FlowJo v.10 software (Tree Star, Stanford University, CA, USA). Single cell mapping was performed using a t-Distributed Stochastic Neighbor Embedding (tSNE) algorithm (33). Gating strategies of flow cytometry data are shown in Supplementary Figures 1–5.

RNA-Sequencing Analysis

Publically available RNA-sequencing data (GSE152904; GSM4629190, GSM4629187, GSM4629184, and GSM4629181) were used for analysis of comprehensive cytokine expression profiles in human CD4+ T cells induced by OX40 signaling (GEO accession). CD4+ T cells were stimulated in vitro in the presence of anti-CD3/CD28 activation beads, with or without agonistic OX40 antibody for 3 to 5 days, after which RNA-sequencing was performed to evaluate OX40-mediated transcriptional changes (34). Gene expression was quantified by RSEM (v1.2.14).
**Statistical Analysis**

Data were analyzed using GraphPad Prism software (Version7; GraphPad Software, La Jolla, CA). Statistical significance was assessed by unpaired or paired 2-tailed Student t-test or repeated measures ANOVA. Two-sided P < 0.05 was considered significant.

**RESULTS**

**Peripheral Tfh Cells Show High Expression of TIGIT**

TIGIT is an immune checkpoint receptor whose expression profile in peripheral CD4+ T cells is not understood in detail. We sought to elucidate its expression profile by first analyzing TIGIT expression in peripheral CD4+ T cells using unbiased tSNE algorithm (33). We found that TIGIT expression mainly came from a CD45RA-CXCR5+CD4+ T cell population, so-called peripheral Tfh cells (Figure 1A). To confirm the relevance of TIGIT expression in Tfh cells, we next comprehensively quantified the proportion of TIGIT+ cells in CD4+ T cell subsets from healthy individuals. We found that approximately 20% of total CD4+ T cells were positive for TIGIT (Figures 1B, C) and that most TIGIT+ CD4+ T cells belonged to the memory fraction (mean 25% versus. 6%, p <0.0001) (Figures 1D, E). We then examined TIGIT expression in memory CD4+ T cells classified into CXCR5+ Tfh and CXCR5- T helper (Th) fractions. We found that the proportion of TIGIT+ cells in the Tfh fraction was twice as high as that in the Th fraction (mean 43% versus. 19%, p <0.0001) (Figures 1F, G). These findings suggested that TIGIT was mainly expressed on peripheral Tfh cells.

**TIGIT Identifies Peripheral Tfh-Cell Populations Producing High Levels of IL-21**

Given that peripheral CXCR5+ Tfh cells produce IL-21 (23, 24), we assessed the association of TIGIT expression with IL-21 production in peripheral Tfh cells by comparing IL-21 production in TIGIT+ Tfh and TIGIT- Tfh cells. Unbiased single cell analysis using the tSNE algorithm demonstrated that TIGIT+ Tfh cells showed high expression of IL-21 (Figure 2A). Unexpectedly, the null hypothesis was confirmed in Th cells regarding the association between TIGIT expression and IL-21; TIGIT- Th cells showed high expression of IL-21 (Figure 2A). To confirm these results, we compared the proportion of IL-21-producing cells between TIGIT+ and TIGIT- Tfh cells from healthy individuals in vitro. The results showed that peripheral TIGIT+ Tfh cells produced more IL-21 than TIGIT- Tfh cells (mean 28% versus 19%, p <0.0001) (Figures 2B, C). Conversely, when we compared IL-21 production between TIGIT+ Th and TIGIT- Th cells, TIGIT- Th cells produced more IL-21 than TIGIT+ Th cells (mean 23% versus 11%, p <0.01) (Figures 2D, E). Thus, peripheral Tfh cells are characterized by high expression of TIGIT, and TIGIT positivity identifies high IL-21-producing Tfh-cell populations. In contrast, the majority of peripheral Th cells do not express TIGIT and TIGIT negativity detects high IL-21-producing Th-cell populations.

**TIGIT Is a Useful Marker for Detecting High IL-21-Producing Populations of Tfh1, Tfh2, and Tfh17 Subsets**

We next hypothesized that TIGIT could be a common surface marker for the detection of high IL-21-producing populations in peripheral Tfh subsets, such as Tfh1, Tfh2, and Tfh17. Single cell mapping of each Tfh and Th cell subset revealed that TIGIT+ Tfh subsets and TIGIT- Th subsets consistently expressed high levels of IL-21 (Supplementary Figure 6). Accordingly, we quantified and compared IL-21 production in respective TIGIT+ Tfh and TIGIT- Tfh subsets. TIGIT positivity commonly revealed high IL-21-producing populations in Tfh1 (21% versus 17%, p <0.01), Tfh2 (25% versus 15%, p <0.001), and Tfh17 (23% versus 17%, p <0.001) subsets (Figures 3A, B). Consistent with this result for high IL-21-producing TIGIT+ Th cell subsets by single cell analysis, TIGIT negativity commonly detected high IL-21-producing populations in Th1 (17% versus 12%, p <0.01), Th2 (17% versus 11%, p <0.01), and Th17 (22% versus 7%, p <0.01) subsets (Figures 3C, D). Thus, although chemokine receptor programming on human Th cells can be plastic (35), TIGIT is a stable marker for detecting IL-21-producing populations in Tfh and Th cells.

**TIGIT Is Not an Activation Marker**

Activated T cells generally produce more cytokines than non-activated T cells. Thus, we asked whether TIGIT was an activation marker for CD4+ T cells. To do so, we assayed PD-L1, a recently recognized activation marker for T cells (36). After stimulation, we observed significant upregulation of PD-L1 in both Tfh and Th cells (Figures 4A, B). In contrast, TIGIT expression in Tfh and Th cells did not show significant changes (Figures 4C, D). To further test that TIGIT was not an activation marker, we used PD-L1 expression levels as activation markers and compared them between TIGIT+ Tfh and TIGIT- Tfh cells after stimulation. The results clearly showed that there was no difference in PD-L1 expression levels between TIGIT+ and TIGIT- Tfh cells (Figure 4E). These data suggest that TIGIT is not an activation marker, but rather identifies high IL-21-producing populations of Tfh cells.

**PD-1 Expression Is Higher in TIGIT+ T Cells Than TIGIT- T Cells**

Recent studies reported that PD-1+ CXCR5- Th cells, so-called T peripheral helper (Tph) cells, effectively produced IL-21 (37–39). Also, PD-1+ CXCR5+ Tfh cells are known to be high IL-21 producers (40). Thus, we next investigated the proportion of PD-1+ cells in TIGIT+ and TIGIT- T cell fractions. TIGIT+ Tfh cells showed higher proportion of PD-1+ cells than TIGIT- Tfh cells (34.7% versus 9.2%, p <0.001) (Figures 5A, B). As well, TIGIT+ Th cells had higher proportion of PD-1+ cells than TIGIT- Th cells (25.4% versus 16.1%, p <0.01) (Figures 5C, D). These
results indicate that high IL-21 production in TIGIT+ Tfh cells may be explained by high proportion of PD-1+ cells in their fraction; however, TIGIT+ Th cells contained more Tph than TIGIT- Th cells, suggesting that some other mechanisms rather than Tph cells might be contributing to high IL-21 production in TIGIT- Th cells.

OX40 Signal Is Associated With High IL-21 Expression

Therefore, we further investigated other molecule which could contribute to high IL-21 production in both TIGIT+ Tfh cells and TIGIT- Th cells. Recently, it has been suggested that OX40 (CD134)-mediated signal is a key contributor to Tfh-associated
responses (41–43). RNA-sequencing analysis revealed that among a total of 49 cytokines, IL-21 expression was clearly induced by OX40 stimulation in CD4+ T cells (Figure 6A). Accordingly, we assumed that TIGIT+ Tfh and TIGIT- Th cells express higher levels of OX40. Flow cytometric analysis found that the proportion of OX40+ cells was higher in TIGIT+ Tfh cells than TIGIT- Tfh cells (7.3% versus 3.7%, p <0.001) (Figures 6B, C). In contrast, TIGIT- Th cells showed a higher proportion of OX40+ cells than TIGIT+ Th cells (11.8% versus 2.0%, p <0.001) (Figures 6D, E). Taken together, these data suggested that TIGIT+ Tfh and TIGIT- Th cells exhibit high IL-21 production via OX40-mediated signal.

**Peripheral TIGIT+ Tfh Populations Are Increased in IgG4-RD**

The identification of high IL-21-producing peripheral TIGIT+ Tfh-cell populations led us to consider whether TIGIT expression in Tfh cells represents accelerated Tfh responses in IgG4-RD. IgG4-RD is a fibro-inflammatory autoimmune disease in which peripheral Tfh, IL-21, and autoantibodies are involved (44–47).

We analyzed the proportion of peripheral high IL-21-producing populations (TIGIT+ Tfh cells and TIGIT- Th cells) in samples from patients with untreated, active IgG4-RD compared to those from healthy individuals. When we examined TIGIT+ cells in total CD4+ T cells, IgG4-RD patients showed higher proportion of TIGIT+ cells than healthy individuals (mean 27% versus 17%, p<0.0001) (Figure 7A). Furthermore, we found that the proportion of TIGIT+ Tfh cells was significantly higher in IgG4-RD patients than in healthy individuals (mean 56% versus 43%, p<0.0001) (Figures 7B, C). We also found that the proportion of TIGIT- Th cells was significantly lower in IgG4-RD patients than in healthy individuals.
individuals (mean 70% versus 80%, *p*<0.001) (Figure 7D). Accordingly, as compared with healthy individuals, the balance of peripheral TIGIT+ Tfh and TIGIT- Th cells was skewed toward TIGIT+ Tfh cells in IgG4-RD (mean 0.84 versus 0.55, *p*<0.001) (Figure 7E). The increased ratio of TIGIT+ Tfh cells to CD4+ T cells or to TIGIT- Tfh cells in IgG4-RD compared to healthy individuals was also confirmed (Figure 7F and Supplementary Figure 7).

Since we found significant skewing toward TIGIT+ Tfh cells in patients with IgG4-RD, we next analyzed the proportion of TIGIT+ Tfh-cell subsets (Tfh1, Tfh2, and Tfh17) among IgG4-RD and healthy individuals (Figures 7G–J). The proportion of peripheral TIGIT+ Tfh1 or TIGIT+ Tfh2 cells in IgG4-RD was significantly higher than that in healthy individuals, whereas the proportion of peripheral TIGIT+ Tfh17 cells was not different between in IgG4-RD and healthy individuals (Figures 7G–J).

The proportion of peripheral TIGIT+ Tfh cells thus appears to be increased in IgG4-RD in which Tfh cells are involved; moreover, the balance of peripheral TIGIT+ Tfh subset (Tfh1, Tfh2, and Tfh17) is characteristically altered. IgG4-RD patients

**FIGURE 3** | The association of TIGIT expression with IL-21 in Tfh and Th subsets. (A–D) CD4+ T cells were stimulated for 4 hours with phorbol myristoyl acetate and ionomycin. Intracellular IL-21 production in TIGIT+ or TIGIT-Tfh cell subsets (Tfh1; CXCR3+CXCR6- cells, Tfh2; CXCR3 CCR6- cells, Tfh17; CXCR3 CCR6+ cells) or TIGIT+ or TIGIT-Th cell subsets (Th1; CXCR3-CCR6- cells, Th2; CXCR3-CCR6- cells, Th17; CXCR3-CCR6- cells) were measured by flow cytometry. (C, E), representative image. (B, D) multiple comparison of the proportion of IL-21 producing cells in Tfh cell subsets or Th cell subsets (n=6). (B, D) paired t-test. "***p<0.001, **p<0.01."
showed an increased proportion of peripheral TIGIT+ Tfh cells, particularly in Tfh1 and Tfh2 populations, compared with healthy individuals.

**The Increases in the Proportion of Peripheral TIGIT+ Tfh Cells Are Associated With Disease Activity in IgG4-RD**

To determine the clinical significance of increased numbers of peripheral TIGIT+ Tfh cells and their subsets, we determined the correlation between these cells and clinical parameters in untreated, active patients. First, we demonstrated the correlation between IL-21 production in Tfh cells and disease activity in patients with active, untreated IgG4-RD (n = 3, **Figure 8A**). As a result, we found that IL-21 production in Tfh cells correlated with the proportion of TIGIT+ cells in Tfh cells, serum IgG4 level, and scores of disease activity even though the significance was not determined. Further analysis of 23 patients with active, untreated IgG4-RD demonstrated that the proportion of TIGIT+ Tfh cells correlated with the scores of IgG4-RD RI, number of affected organs and soluble IL-2 receptors, and serum levels of IgG and IgG4 (**Figure 8B**). The proportion of TIGIT+ Tfh2 cells also correlated with these clinical parameters; this correlation was stronger than that of TIGIT+ Tfh cells (**Figure 8B**). In contrast, the proportion of TIGIT- Th cells negatively correlated with the
scores of IgG4-RD RI and serum levels of IgG and IgG4 (Figure 8B). There was no significant correlation between the proportion of TIGIT+ Tfh1 cells and clinical parameters (Figure 8B).

Atopic parameters (serum IgE level or blood eosinophil count) or serum C-reactive protein levels did not correlate with the proportion of any immune cell subsets in IgG4-RD (Figure 8B). Consistent with this finding, the increase of peripheral TIGIT+ Tfh cells in IgG4-RD did not depend on the atopic history of patients (Figure 8C).

Recent cross-sectional studies in international cohorts have revealed that IgG4-RD patients can be divided into 4 groups based on clinical phenotype: group 1, Pancreato-Hepato-Biliary disease; group 2, Retroperitoneal Fibrosis and/or Aortitis; group 3, Head and Neck-limited disease; and group 4, classic Mikulicz syndrome with systemic involvement (48). We correlated the proportion of peripheral TIGIT+ Tfh, TIGIT+ Tfh1, TIGIT+ Tfh2, and TIGIT- Th cells with these clinical groupings. We compared the proportion of these cell subsets between groups 3 and 4 (Figure 8D). Groups 1 and 2 could not be evaluated because of small patient numbers (1 for G1 and 2 for G2). Compared with group 3, group 4 had a higher proportion of TIGIT+ Tfh cells (mean 65% versus 54%, p<0.05) and TIGIT+ Tfh2 cells (mean 65% versus 56%, p<0.05), but not of TIGIT+ Tfh1 cells (mean 65% versus 65%, p=0.92) or TIGIT- Th cells (mean 68% versus 70%, p=0.72) (Figure 8D). Group 4 also had higher disease activity scores (mean 15 versus 10, p<0.01) and levels of serum IgG (mean 2120mg/dL versus 1551mg/dL, p<0.01) (Supplementary Figure 8), and serum IgG4 level tended to be higher in group 4 than group 3 (752mg/dL versus 440mg/dL, p=0.07) (Supplementary Figure 8). Collectively, the increased proportion of peripheral TIGIT+ Tfh and TIGIT+ Tfh2 cells reflected higher disease activity in patients with untreated, active IgG4-RD.

Peripheral TIGIT+ Tfh Cells in IgG4-RD Are Decreased Following Treatment With Glucocorticoids

To evaluate the effects of glucocorticoid treatment on the proportions of peripheral TIGIT+ Tfh, TIGIT+ Tfh1, and TIGIT+ Tfh2 cells and on clinical improvement, we evaluated seven patients with IgG4-RD before and after 12 weeks of glucocorticoid treatment. The proportion of peripheral TIGIT+ Tfh, TIGIT+ Tfh1, and TIGIT+ Tfh2 cells significantly decreased after glucocorticoid treatment (TIGIT+ Tfh, 59% versus 43%, p<0.01; TIGIT+ Tfh1, 65% versus 51%, p<0.05; and TIGIT+ Tfh2, 66% versus 45%, p<0.01), while the proportion of total CD4+ T cells did not significantly decrease (47% versus 51%, p>0.05) (Figures 9A–E). Serum IgG and IgG4 levels and disease activity scores also decreased (mean 2209mg/dL versus 980mg/dL, p<0.01; mean 868mg/dL versus 147mg/dL, p<0.05; and mean 14 versus 2, p<0.001, respectively) (Figures 9F–H).
DISCUSSION

In this study, we found that peripheral Tfh cells have higher expression of TIGIT than Th cells. Of note, TIGIT+ Tfh cells produced more IL-21 than TIGIT- Tfh cells. TIGIT positivity commonly identified high IL-21-producing populations on analysis of Tfh subsets (Tfh1, Tfh2, and Tfh17). OX40 signal was associated with high IL-21 expression, and TIGIT+ Tfh cells exhibited higher OX40 expression than TIGIT- Tfh cells. Importantly, the proportion of peripheral TIGIT+ Tfh and
TIGIT+ Tfh2 cells was increased in patients with IgG4-RD, correlating with disease activity. These findings suggest that OX40 is associated with high IL-21 production in TIGIT+ Tfh cells and the increase of TIGIT+ Tfh cells reflects disease activity in IgG4-RD.

TIGIT positivity was associated with high production of IL-21 in peripheral Tfh cells, whereas TIGIT negativity was linked to high production of IL-21 in peripheral Th cells. The biological significance that there is a positive correlation of IL-21 production in Tfh but not Th cells might be derived from OX40 but not Tph cells. In fact, the proportion of Tph in TIGIT- Th cells was lower than in TIGIT+ Th cells, whereas both TIGIT+ Tfh and TIGIT- Th cells showed high expression of OX40. Furthermore, we showed that OX40 signal was associated with high IL-21 expression. Thus, we believe that OX40 signal contributes to high IL-21 production in...
The association of proportion of TIGIT+ Tfh cells with disease activity and history of atopy of IgG4-RD. Correlation of IL-21 production in Tfh with disease activity was examined in 3 patients with untreated, active IgG4-RD (A). Correlation of TIGIT+ Tfh, TIGIT+ Tfh1, TIGIT+ Tfh2, and TIGIT- Th with clinical parameters in 23 patients with active, untreated IgG4-RD are shown as heat maps (B). The proportion of TIGIT+ Tfh, TIGIT+ Tfh1, TIGIT+ Tfh2, and TIGIT- Th was compared between patients with an atopic history and those without (C). The proportion of TIGIT+ Tfh, TIGIT+ Tfh1, TIGIT+ Tfh2, and TIGIT- Th are shown based on each clinical phenotype (groups 1-4). Statistical comparison was performed on groups 3 and 4 (D). (B) Spearman’s correlation coefficient. (C, D) unpaired t test. ***p<0.0001, **p<0.001, *p<0.01, ns p>0.05.
Thus, we assume that IL-21-producing cells are associated with disease activity and the pathogenesis of IgG4-RD. The low number of patients in groups 1 (Pancreato-Hepato-Biliary disease; n=1) and group 2 (Retroperitoneal Fibrosis and/or Aortitis; n=2) were insufficient to support statistical analysis. Nevertheless, we did make the interesting observation that both patients in group 2 had extremely high levels of TIGIT+ Tfh2 cells (68% and 71%) compared to healthy individuals (41%). The patient comprising group 1 had lower levels of TIGIT+ Tfh2 cells (30%) than healthy individuals. Accordingly, differential dysregulation of peripheral Tfh subsets responses might correlate with the different clinical phenotypes observed. Further studies are needed to support this idea.

Our present study has the limitation. We did not show the localization of TIGIT+ Tfh cells in the lesions of patients with IgG4-RD. Recent studies reported that Tfh and Tfh2 cells are infiltrated in the affected tissues of IgG4-RD (6, 9, 14). The co-localization of Tfh cells with B cells within ectopic germinal centers at the lesions of IgG4-RD was found (52). Furthermore, Maehara et al. reported that the infiltration of IL-4-producing Tfh cells presented outside of the ectopic germinal centers at lesions of IgG4-RD (10), while IL-21-producing Tfh cells presented inside of the ectopic germinal centers (20), indicating that IL-21-producing TIGIT+ Tfh cells may localize inside the ectopic germinal centers interacting with B cells.

In conclusion, OX40 is associated with high IL-21-producing peripheral TIGIT+ Tfh-cell populations, and the increase in TIGIT+ Tfh cells reflects disease activity in IgG4-RD. Our findings suggest that TIGIT may be a useful marker for detecting IL-21-producing Tfh cells and a potential therapeutic target.

DATA AVAILABILITY STATEMENT

The datasets presented in this study can be found in online repositories. The names of the repository/repositories and accession number(s) can be found in the article/Supplementary Material.

ETHICS STATEMENT

The studies involving human participants were reviewed and approved by Keio University School of Medicine. The patients/...
participants provided their written informed consent to participate in this study.

**AUTHOR CONTRIBUTIONS**

Study design: MA. Data acquisition: MA, KS, KY, HY, YK, and TT. Data analysis and interpretation: MA, KS, and KY. Manuscript drafting: MA, KS, KY, and TT. All authors contributed to the article and approved the submitted version.

**REFERENCES**

1. Perugino CA, Stone JH. IgG4-related disease: an update on pathophysiology and implications for clinical care. *Nat Rev Rheumatol* (2020) 16:702–14. doi: 10.1038/s41584-020-0500-7
2. Lanzillotta M, Mancuso G, Della-Torre E. Advances in the diagnosis and management of IgG4 related disease. *BMJ* (2020) 369:m1067. doi: 10.1136/bmj.m1067
3. Akiyama M, Takeuchi T. IgG4-related Disease: Beyond Glucocorticoids. *Drugs Aging* (2018) 35:275–87. doi: 10.1007/s40266-018-0534-6
4. Akiyama M, Kaneko Y, Takeuchi T. Characteristics and prognosis of IgG4-related periaortitis/periarтерitis: A systematic literature review. *Autoimmun Rev* (2019) 18:102354. doi: 10.1016/j.autrev.2019.102354
5. Akiyama M, Suzuki K, Yasuoka H, Kaneko Y, Yamaoka K, Takeuchi T. Follicular helper T cells in the pathogenesis of IgG4-related disease. *Rheumatol (Oxford)* (2018) 57:236–45. doi: 10.1093/rheumatology/key171
6. Kamikura R, Takano K, Yamamoto M, Kawata K, Shigehara K, Itsukawa S, et al. Cutting Edge: A Critical Role of Lymphatic T Follicular Helper Cells in the Pathogenesis of IgG4-related Disease. *J Immunol* (2017) 199:2624–9. doi: 10.4049/jimmunol.1601507
7. Kubo S, Nakayamada S, Zhao J, Yoshikawa M, Miyazaki Y, Nawata A, et al. Correlation of T follicular helper cells and plasmablasts with the development of organ involvement in patients with IgG4-related disease. *Rheumatol Rheumatol (Oxford)* (2018) 57:514–24. doi: 10.1093/rheumatology/keh455
8. Grados A, Ebbo M, Piperoglou C, Groh M, Regent A, Samson M, et al. T Cell Polarization toward T H 2/T FH 2 and T H 17/T FH 17 in Patients with IgG4-related Disease. *Front Immunol* (2017) 8:235. doi: 10.3389/fimmu.2017.00235
9. Chen Y, Lin W, Yang H, Wang M, Zhang P, Feng R, et al. Aberrant Expansion and Function of Follicular Helper T Cell Subsets in IgG4-related Disease. *Arthritis Rheumatol* (2018) 70:1853–65. doi: 10.1002/art.40556
10. Kubo S, Nakayamada S, Zhao J, Yoshikawa M, Miyazaki Y, Nawata A, et al. Correlation Of T Follicular Helper Cells And Plasmablasts With The Development Of Organ Involvement In Patients With IgG4-related Disease. *Rheumatol Rheumatol (Oxford)* (2018) 57:514–24. doi: 10.1093/rheumatology/keh455
11. Akiyama M, Suzuki K, Yasuoka H, Kaneko Y, Takeuchi T. Follicular helper T cells in the pathogenesis of IgG4-related disease. *Rheumatol (Oxford)* (2018) 57:236–45. doi: 10.1093/rheumatology/key171
12. Akiyama M, Suzuki K, Yasuoka H, Kaneko Y, Kondo H, et al. Enhanced IgG4 production by follicular helper 2 T cells and the involvement of follicular helper 1 T cells in the pathogenesis of IgG4-related disease. *Arthritis Res Ther* (2016) 18:167. doi: 10.1186/s13075-016-1064-4
13. Higashioka K, Ota Y, Maehara T, Moriyama M, Ayano M, Mitoma H, et al. Association of circulating SLAMF7 + Tfh1 cells with IgG4 levels in patients with IgG4-related disease. *BMC Immunol* (2020) 21:31. doi: 10.1186/s12865-020-00361-0
14. Cargill T, Makuch M, Sadler R, Lighaam LC, Peters R, van Ham M, et al. Activated T-Follicular Helper 2 Cells Are Associated With Disease Activity in IgG4-related Sclerosing Cholangitis and Pancreatitis. *Clin Transl Gastroenterol* (2019) 10:e00020. doi: 10.14309/ctg.0000000000000020
15. Takahashi S, Akiyama M, Suzuki K, Otomo K, Takeuchi T. IgG4-related fibrosing mediastinitis diagnosed with computed tomography-guided percutaneous needle biopsy: Two case reports and a review of the literature. *Med (Baltimore)* (2018) 97:e10935. doi: 10.1097/MD.00000000000010935

**FUNDING**

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2021.651357/full#supplementary-material
31. Carruthers MN, Stone JH, Deshpande V, Khostronshahi A. Development of an IgG4-RD Responder Index. *Int J Rheumatol* (2012) 2012:259408. doi: 10.1155/2012/259408

32. Cossarizza A, Chang HD, Radbruch A, Akdis M, Andra I, Annunziato F, et al. Guidelines for the use of flow cytometry and cell sorting in immunological studies. *Eur J Immunol* (2017) 47:1584–797. doi: 10.1002/eji.201646632

33. Amir el AD, Davis KL, Tadmor MD, Simonds EF, Levine JH, Bendall SC, et al. viSNE enables visualization of high dimensional single-cell data and reveals phenotypic heterogeneity of leukemia. *Nat Biotechnol* (2013) 31:545–52. doi: 10.1038/nbt.2594

34. Campos Carrascosa L, van Beek AA, de Ruiter V, Doukas M, Wei J, Fisher TS, et al. FCRIIB engagement drives agonistic activity of Fc-engineered oOX40 antibody to stimulate human tumor-infiltrating T cells. *J Immunother Cancer* (2020) 8:e000816. doi: 10.1136/jitc-2020-000816

35. Sallusto F. Heterogeneity of Human CD4(+) T Cells Against Microbes. *Curr Opin Microbiol* (2003) 6:467–71. doi: 10.1016/S1369-5274(03)00099-X

36. Diskin B, Adam S, Cassini MF, Sanchez G, Liria M, Aylut B, et al. PD-L1 engagement on T cells promotes self-tolerance and suppression of neighboring macrophages and effector T cells in cancer. *Nat Immunol* (2020) 21:442–54. doi: 10.1038/s41590-020-0620-x

37. Bocharnikov AV, Keegan J, Wacleche VS, Cao Y, Fonseka CY, Wang G, et al. P10-19CXCR5- T peripheral helper cells promote B cell responses in lupus via MAF and IL-21. *JCI Insight* (2019) 4:e130062. doi: 10.1172/jci.insight.130062

38. Rao DA. T Cells That Help B Cells in Chronically Inflamed Tissues. *Front Immunol* (2018) 9:1924. doi: 10.3389/fimmu.2018.01924

39. Rao DA, Guriš MF, Marshall JL, Slowikowski K, Fonseka CY, Liu Y, et al. Pathologically expanded peripheral T helper cell subset drives B cells in rheumatoid arthritis. *Nature* (2017) 542:110–4. doi: 10.1038/nature20810

40. Ueno H. T follicular helper cells in human autoimmunity. *Curr Opin Immunol* (2016) 43:24–31. doi: 10.1016/j.coi.2016.08.003

41. Kurata I, Matsumoto I, Ohyama A, Osada A, Ebe H, Kawaguchi H, et al. Potential involvement of OX40 in the regulation of autoantibody sialylation in arthritis. *Ann Rheum Dis* (2019) 78:1488–96. doi: 10.1136/annrheumdis-2019-215195

42. Pattarini I, Trichot C, Bogiatzi S, Grandclaudon M, Meller S, Kevylian Z, et al. TSLP-activated dendritic cells induce human T follicular helper cell differentiation through OX40-ligand. *J Exp Med* (2017) 214:1529–46. doi: 10.1084/jem.20150402

43. Jacquemin C, Schmitt N, Contin-Bordes C, Liu Y, Narayanan P, Seneschal J, et al.OX40 Ligand Contributes to Human Lupus Pathogenesis by Promoting T Follicular Helper Response. *Immunity* (2015) 42:1159–70. doi: 10.1016/j.immuni.2015.05.012

44. Perugino CA, AlSalem SB, Mattow H, Della-Torre E, Mahajan V, Ganesh G, et al. Identification of galectin-3 as an autoantigen in patients with IgG4-related disease. *J Allergy Clin Immunol* (2019) 143:756–765.e6. doi: 10.1016/j.jaci.2018.05.011

45. Liu H, Perugino CA, Ghebreemichael M, Wallace ZS, Montesi SB, Stone JH, et al. Disease Severity Linked to Increased in Autoantibody Diversity in IgG4-Related Disease. *Arthritis Rheumatol* (2020) 72:687–93. doi: 10.1002/art.41140

46. Hubers LM, Vos H, Schuurman AR, Erken R, Oude Elferink RP, Burgering B, et al. Annexin A11 is targeted by IgG4 and IgG1 autoantibodies in IgG4-related disease. *Gut* (2018) 67:728–35. doi: 10.1136/gutjnl-2017-314548

47. Shiokawa M, Kodama Y, Sekiguchi K, Kuwada T, Tomono T, Kuriyama K, et al. Laminin 511 is a target antigen in autoimmune pancreatitis. *Sci Transl Med* (2018) 10:eaaq0997. doi: 10.1126/scitranslmed.aaq0997

48. Wallace ZS, Zhang Y, Perugino CA, Naden R, Choi HK, Stone JH, et al. Clinical phenotypes of IgG4-related disease: an analysis of two international cross-sectional cohorts. *Ann Rheum Dis* (2019) 78:406–12. doi: 10.1136/annrheumdis-2018-214603

49. Ramos-Casals M, Brahmer JR, Callahan MK, Flores-Chávez A, Keegan N, Khamashita MA, et al. Immune-related adverse events of checkpoint inhibitors. *Nat Rev Dis Primers* (2020) 6:38. doi: 10.1038/s41572-020-0160-6

50. Marinkovic T, Marinkovic D. Biological mechanisms of ectopic lymphoid structure formation and their pathophysiological significance. *Int Rev Immunol* (2020) 7:1–13. doi: 10.3109/08830189098061761

51. Dixon KO, Schorer M, Nevin J, Etminan Y, Amoozgar Z, Kondo T, et al. Functional Anti-TIGIT Antibodies Regulate Development of Autoimmunity and Antitumor Immunity. *J Immunol* (2018) 200:3000–7. doi: 10.4049/jimmunol.1700407

52. Zaidan M, Cervera-Pierot P, Seigneux S, Dahan K, Fabiani B, Callard P, et al. Evidence of follicular T-cell implication in a case of IgG4-related systemic disease with interstitial nephritis. *Nephrol Dial Transplant* (2011) 26:2047–50. doi: 10.1093/ndt/gfr097

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.